MolDX: Breast Cancer Index® (BCI) Gene Expression Test

This policy provides limited coverage for the Breast Cancer Index (BCI) gene expression test (Biotheranostics) for postmenopausal women with invasive ER+ and/or PR+, HER2- early-stage breast cancer (T1-T3, pN0-pN1, M0) when there is no evidence of distant metastasis and the results will be used to guide chemotherapy and/or endocrine therapy decisions. Coverage is restricted to this specific test and is not applicable to patients outside these receptor, staging, menopausal status, or intent-to-treat-management criteria.

"Coverage is provided for the Breast Cancer Index (BCI) gene expression test (Biotheranostics) for evaluation of distant recurrence risk and endocrine responsiveness to inform chemotherapy and/or en..."

Sign up to see full coverage criteria, indications, and limitations.